Fibroblast growth factor-21-Fc fusion proteins
US11944664B2 · kind B2 · utility
0Cited by
7References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 24, 2021 |
| Grant date | Apr 2, 2024 |
| Priority date | — |
| Expiry date | Aug 24, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to the identification of fusion proteins comprising polypeptide and protein variants of fibroblast growth factor 21 (FGF21) with improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.